Mainland Chinese developer Country Garden gets Hong Kong court-backed debt lifeline


Country Garden Holdings has cleared a major hurdle this week after securing approval for both its onshore and offshore restructuring plans, offering the embattled developer a lifeline amid mainland China’s property downturn.

Sources said the Hong Kong High Court on Thursday endorsed a proposal allowing the indebted developer, once the country’s largest homebuilder by sales, to extend repayment of US$17.7 billion in offshore debt. The creditors now have the option to swap their debt for shares, receive convertible bonds or accept new notes.

The company also disclosed that onshore bondholders had agreed to extend nine bonds worth 13.8 billion yuan (US$1.95 billion) on Wednesday. Domestic creditors were given the option to either sell the bonds back to the company at a discount, convert debt into equity or retain their claims as general creditors.

The two restructuring plans were expected to reduce Country Garden’s total debt by more than 90 billion yuan and significantly ease repayment pressure over the next five years, according to the company. It added that financing costs for most new debt instruments were expected to drop sharply – to between 1 per cent and 2.5 per cent.

Mainland China’s property market is in the fifth year of a slump. Photo: AFP
Mainland China’s property market is in the fifth year of a slump. Photo: AFP

The approval of the plans marked a new phase for the company, according to Liu Shui, director of corporate research at China Index Academy, a real estate research firm. “This could help to rapidly restore normal business operations,” Liu added.

  • Related Posts

    China’s AI red-packet battle burns through US$1 billion – but will users stick around?

    In an unprecedented Chinese New Year marketing blitz, Alibaba Group Holding, Baidu, ByteDance and Tencent Holdings spent an estimated 8 billion yuan (US$1.1 billion) to turn their artificial intelligence assistants…

    Continue reading
    Chinese AI drug researcher XtalPi expects to turn first annual profit on 193% revenue jump

    Chinese artificial intelligence-powered drug researcher XtalPi Holdings said it expects to turn its first annual profit on the back of strong revenue growth, according to a corporate filing. The Shenzhen-based…

    Continue reading

    Leave a Reply

    Your email address will not be published. Required fields are marked *